Literature DB >> 9665650

Effect of deferoxamine and allopurinol on non-protein-bound iron concentrations in plasma and cortical brain tissue of newborn lambs following hypoxia-ischemia.

M Shadid1, G Buonocore, F Groenendaal, R Moison, M Ferrali, H M Berger, F van Bel.   

Abstract

Reduction of non-protein-bound iron (NPBI) using iron chelators may attenuate hypoxia-ischemia-induced reperfusion injury of the brain. This study investigated whether administration of low-dose deferoxamine and allopurinol, both having NPBI-chelating properties, reduced hypoxia-ischemia-induced NPBI formation in plasma effluent from the brain and in cerebral cortical tissue. Twenty-one newborn lambs underwent severe hypoxia-ischemia. Upon reperfusion and reoxygenation the lambs received either a placebo (n = 7), or deferoxamine 2.5 mg/kg (n = 7) or allopurinol 20 mg/kg (n = 7). The post-hypoxic-ischemic NPBI levels in plasma were significantly lower after deferoxamine but not after allopurinol as compared to placebo-treated lambs. Cortical NPBI levels in both deferoxamine and allopurinol-treated lambs were significantly lower than NPBI levels in placebo-treated lambs. We conclude that deferoxamine effectively lowers NPBI in plasma effluent from the brain, and that both, deferoxamine and allopurinol, lower NPBI in cortical brain tissue.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665650     DOI: 10.1016/s0304-3940(98)00303-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

1.  Iron and iron regulatory proteins in amoeboid microglial cells are linked to oligodendrocyte death in hypoxic neonatal rat periventricular white matter through production of proinflammatory cytokines and reactive oxygen/nitrogen species.

Authors:  Gurugirijha Rathnasamy; Eng-Ang Ling; Charanjit Kaur
Journal:  J Neurosci       Date:  2011-12-07       Impact factor: 6.167

2.  A comparative study on oxidative stress role in nasal breathing impairment and obstructive sleep apnoea syndrome.

Authors:  D Passali; G Corallo; A Petti; M Longini; F M Passali; G Buonocore; L M Bellussi
Journal:  Acta Otorhinolaryngol Ital       Date:  2016-12       Impact factor: 2.124

3.  Docosahexaenoic acid enhances iron uptake by modulating iron transporters and accelerates apoptotic death in PC12 cells.

Authors:  Eldi Schonfeld; Ilanit Yasharel; Ephraim Yavin; Annette Brand
Journal:  Neurochem Res       Date:  2007-06-06       Impact factor: 3.996

Review 4.  New antioxidant drugs for neonatal brain injury.

Authors:  Maria Luisa Tataranno; Serafina Perrone; Mariangela Longini; Giuseppe Buonocore
Journal:  Oxid Med Cell Longev       Date:  2015-01-05       Impact factor: 6.543

Review 5.  Oxidative stress in patients with obstructive sleep apnoea syndrome.

Authors:  D Passali; G Corallo; S Yaremchuk; M Longini; F Proietti; G C Passali; L Bellussi
Journal:  Acta Otorhinolaryngol Ital       Date:  2015-12       Impact factor: 2.124

Review 6.  Role of Antioxidants in Neonatal Hypoxic-Ischemic Brain Injury: New Therapeutic Approaches.

Authors:  Olatz Arteaga; Antonia Álvarez; Miren Revuelta; Francisco Santaolalla; Andoni Urtasun; Enrique Hilario
Journal:  Int J Mol Sci       Date:  2017-01-28       Impact factor: 5.923

7.  Effect of allopurinol in addition to hypothermia treatment in neonates for hypoxic-ischemic brain injury on neurocognitive outcome (ALBINO): study protocol of a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III).

Authors:  Christian A Maiwald; Kim V Annink; Mario Rüdiger; Manon J N L Benders; Frank van Bel; Karel Allegaert; Gunnar Naulaers; Dirk Bassler; Katrin Klebermaß-Schrehof; Maximo Vento; Hercilia Guimarães; Tom Stiris; Luigi Cattarossi; Marjo Metsäranta; Sampsa Vanhatalo; Jan Mazela; Tuuli Metsvaht; Yannique Jacobs; Axel R Franz
Journal:  BMC Pediatr       Date:  2019-06-27       Impact factor: 2.125

Review 8.  Targeting Ferroptosis: Pathological Mechanism and Treatment of Ischemia-Reperfusion Injury.

Authors:  Xinye Li; Ning Ma; Juping Xu; Yanchi Zhang; Pan Yang; Xin Su; Yanfeng Xing; Na An; Fan Yang; Guoxia Zhang; Lijing Zhang; Yanwei Xing
Journal:  Oxid Med Cell Longev       Date:  2021-10-28       Impact factor: 6.543

9.  CeRebrUm and CardIac Protection with ALlopurinol in Neonates with Critical Congenital Heart Disease Requiring Cardiac Surgery with Cardiopulmonary Bypass (CRUCIAL): study protocol of a phase III, randomized, quadruple-blinded, placebo-controlled, Dutch multicenter trial.

Authors:  Raymond Stegeman; Maaike Nijman; Nicolaas J G Jansen; Manon J N L Benders; Johannes M P J Breur; Floris Groenendaal; Felix Haas; Jan B Derks; Joppe Nijman; Ingrid M van Beynum; Yannick J H J Taverne; Ad J J C Bogers; Willem A Helbing; Willem P de Boode; Arend F Bos; Rolf M F Berger; Ryan E Accord; Kit C B Roes; G Ardine de Wit
Journal:  Trials       Date:  2022-02-23       Impact factor: 2.279

10.  Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.

Authors:  Wan-Yu Chu; Kim V Annink; Karel Allegaert; Alwin D R Huitema; A Laura Nijstad; Christian A Maiwald; Michael Schroth; Loubna El Bakkali; Frank van Bel; Manon J N L Benders; Mirjam M van Weissenbruch; Anja Hagen; Axel R Franz; Thomas P C Dorlo
Journal:  Clin Pharmacokinet       Date:  2021-10-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.